23 Jan 2017 13:00
For immediate release | 23 January 2017 |
Futura Medical plc
("Futura" or "the Company")
Notice of Preliminary Results
Futura Medical plc (AIM: FUM), the innovative healthcare company focused on advanced transdermal technology, will announce its preliminary results for the year ended 31 December 2016 on Thursday 23 March 2017.
A briefing for analysts will be held at 10.00am on the morning of the results at the offices of Buchanan, 107 Cheapside, London EC2V 6DN.
There will be a webcast of the analyst presentation. If you would like to listen to the webcast, please log on to the following web address approximately 5 minutes before 10.00am on the day of results:
http://vm.buchanan.uk.com/2017/futuramedical230317/registration.htm
A recording of the webcast will also be made available at www.futuramedical.com and www.buchanan.uk.com, following the results meeting. For more information, or to register attendance, please contact Buchanan on 020 7466 5000.
For further information please contact:
Futura Medical plc | |
James Barder, Chief Executive | Tel: +44 (0) 1483 685 670 |
Email to: james.barder@futuramedical.com | www.futuramedical.com |
N+1 Singer (Nominated Adviser and Broker) | |
Aubrey Powell / Liz Yong | Tel:+44 (0) 20 7496 3000 |
For media enquiries please contact: | |
Buchanan | |
Mark Court / Sophie Cowles / Stephanie Watson | Tel: +44 (0) 20 7466 5000 |
Notes to Editors
Futura Medical plc
Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.
Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.
www.futuramedical.com
Futura Medical (FUM)